alexa Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned?


Journal of Nuclear Medicine & Radiation Therapy

Author(s): Vijayakrishnan R, Shields CL, Ramasubramanian A, Emrich J, Rosenwasser R,

Abstract Share this page

Abstract OBJECTIVE: To evaluate irradiation toxic effects from fluoroscopy during intra-arterial chemotherapy for retinoblastoma. DESIGN: Prospective trial. PARTICIPANTS: Eight patients treated with intra-arterial chemotherapy. MAIN OUTCOME MEASURES: Irradiation toxic effects in vital organs. RESULTS: The mean patient age was 29 months (range, 10-74 months) and 63\% were male. The mean irradiation dose to the skin of the affected eye was 0.19173 Gy, to the contralateral eye was 0.03533 Gy, to the chest wall was 0.00296 Gy, and to the abdominal wall was 0.00104 Gy. The estimated irradiation dose to the lens in the treatment eye was 0.16 Gy, which, in accumulated doses, could be cataractogenic. The estimated irradiation dose from a single fluoroscopy session to other organs, including the brain (0.05560 Gy), thyroid (0.00192 Gy), bone marrow (0.00059 Gy), and gonads (0.00015 Gy), was far lower than the minimal toxic level. CONCLUSIONS: Careful use of fluoroscopy during intra-arterial chemotherapy with limited irradiation exposure is advised. Accumulated irradiation toxic effects following multiple sessions of intra-arterial chemotherapy could be cataractogenic and possibly carcinogenic, especially in irradiation-sensitive patients with retinoblastoma. This article was published in Arch Ophthalmol and referenced in Journal of Nuclear Medicine & Radiation Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version